Autoinjectors Market CAGR to Exceed 6.2% by 2035, Due To The Growing Demand For Biologics | Roots Analysis

According to our latest market report "Global Autoinjectors Market" by Usability, Route of Administration, Type of Molecule Delivered, Type of Actuation Mechanism, Volume of Container, End User, Target Indication and Key Geographical Regions: Industry Trends and Global Forecasts, till 2035", the global autoinjectors market size is projected to reach around USD 176 billion by 2035 from USD 96.2 billion, growing at a CAGR of 6.2% in the forecast period 2024-2035.

To request quote of this report, please visit:
https://www.rootsanalysis.com/reports/autoinjectors-market/request-quote.html

Autoinjectors are drug delivery devices designed to deliver a dose of a specific drug, often through self-administration. These devices are extensively used for emergency and personal therapy, by delivering drugs via subcutaneous or intramuscular routes. Further, autoinjectors are extremely valuable in immediate treatment during chronic diseases conditions such as anaphylaxis, diabetes, migraine, multiple sclerosis, status epilepticus and rheumatoid arthritis.
Global Autoinjectors Market Segments
Based on usability, the market is segmented into disposable autoinjector and reusable auto injector.

1. The disposable autoinjector segment dominates the autoinjectors market by capturing close to 90% of the overall revenue share, in 2024.
2. The reusable auto injector segment is anticipated to be the fastest growing segment in this industry, with annualized rate (CAGR) of over 7% during the forecast period.

Based on the route of administration, the market is segmented into intramuscular and subcutaneous route.

1. The autoinjectors designed for subcutaneous drug delivery captures the largest revenue share of close to 90% in the autoinjectors market, in 2024.
2. The autoinjectors designed for subcutaneous drug delivery is anticipated to be the fastest growing segment in this industry, with annualized rate (CAGR) of 6.5% during the forecast period.

Based on the type of molecule delivered, the market is segmented into antibodies, proteins, peptides, small molecules and others.

1. The autoinjectors delivering proteins capture the largest revenue share of close to 50% in the autoinjectors market, in 2024.
2. The autoinjectors delivering peptides is anticipated to be the fastest growing segment in this industry, with annualized rate (CAGR) of over 14% during the forecast period.

Based on the type of actuation mechanism, the market is segmented into manual actuation and automatic actuation.

1. The autoinjectors with automatic actuation mechanism capture the largest revenue share of around 80% in the autoinjectors market, in 2024.
2. The autoinjectors with automatic actuation mechanism is anticipated to show the highest annualized growth rate of 6.5% during the forecast period.

Based on the volume of container, the market is segmented into less than 1 mL, 1-2 mL and more than 2 mL

1. The autoinjectors capable of storing 1-2 mL of drug captures the largest revenue share of close to 40% in the autoinjectors market, in 2024.
2. The autoinjectors capable of storing more than 2 mL is anticipated to be the fastest growing segment in this industry, with annualized rate (CAGR) of 8% during the forecast period.

Based on end user, the market is segmented into ambulatory surgical centers, home care settings, and hospitals and clinics.

1. The autoinjectors for home care settings currently dominate the autoinjectors market, by capturing 80% of the overall revenue share, in 2024.
2. The autoinjector for home care settings is anticipated to be the fastest growing segment in this industry, with annualized rate (CAGR) of over 6.5% during the forecast period.

Based on the target indication, the market is segmented into anaphylaxis, diabetes, weight loss, migraine, multiple sclerosis, rheumatoid arthritis, and others.

1. The autoinjectors intended for the treatment of rheumatoid arthritis are anticipated to dominate the current autoinjectors market, by capturing 25% share in the year 2024.
2. Autoinjectors intended for treatment of weight loss is anticipated to be the fastest growing segment in this industry, with annualized rate (CAGR) of more than 16% during the forecast period.

Based on the Regional Insights, the market is segmented North America, Europe, Asia-Pacific, Middle East and North Africa and Latin America

1. North America is likely to dominate the autoinjectors market, by capturing the largest revenue share of close to 55%, in 2024.
2. In Asia Pacific, the autoinjectors market is likely to demonstrate considerable growth (CAGR of around 8%) during the forecast period.

To request a sample copy / brochure of this report, please visit https://www.rootsanalysis.com/reports/autoinjectors-market/request-sample.html

Autoinjectors Regional Outlook
Based on the key geographical regions, the autoinjectors market can be segmented into six major regions, including North America, Europe, Asia Pacific, Middle East and North Africa, and Latin America. North America is anticipated to capture the majority share in the autoinjectors market in 2024 and this trend is likely to remain unchanged during the forecast period. However, Asia Pacific is accounted to be the fastest-growing segment of the market, owing to the growing population, rising prevalence of chronic diseases and favorable reimbursements in this region.

Key Report Takeaways
1. Presently, close to 150 autoinjectors are available / being manufactured by various players, across the world; further, most of the autoinjector manufacturers are based in North America
2. Currently, most of the commercialized autoinjectors are suitable for administering the drug through the subcutaneous route; these autoinjectors are integrated with audible and visual indicators, and can deliver various type of drugs
3. In order to enhance their product portfolios and obtain a competitive edge, firms are constantly integrating novel features in their autoinjectors
4. To cater to the rising demand for autoinjectors, several firms have stepped up to introduce technologically advanced platforms and establish a strong brand position in this industry
5. Over 50% of the agreements in the autoinjectors domain were inked in the last three years; additionally, most of the intercontinental as well as intracontinental deals have been signed by players headquartered in Europe
6. Since 2019, more than 1,100 patents related to autoinjectors have been filed by / granted to different stakeholders in order to protect the intellectual property generated within this domain
7. Nearly 160 autoinjector combination products (with different drugs) have been approved by regulatory authorities, across the world; further, the landscape of autoinjector combination product developers is dominated by very large firms
8. Majority of the commercialized autoinjector combination products are compatible with syringes, and are intended to be used in home settings by adults
9. Over 70 autoinjector combination products are currently being evaluated in early and late stages of development; most of the developers for these products are publicly listed companies
10. Around 90% of the underdeveloped combination products are currently in different clinical phases of development; majority of these are being developed for the treatment of chronic conditions (primarily rheumatoid arthritis)
11. The autoinjectors market is anticipated to grow at a steady rate, till 2035; the projected opportunity is likely to be distributed across type of molecule delivered, usability, route of administration, actuation mechanism, volume of container, target indication, end-user and key geographical location.

Browse Full Report Description + Research Methodology + Table of Content + Infographics here: https://www.rootsanalysis.com/reports/autoinjectors-market/293.html

Autoinjector Market Key Players
Examples of key players in autoinjectors market (which have also been profiled in this market report; the complete list of companies is available in the full report) include Amgen, Antares Pharma, ChemProtect.SK, Elcam Medical, Eli Lilly and Company, Jiangsu Delfu Medical Device, Kindeva Drug Delivery, Merck, Novartis, Novo Nordisk, Oval Medical Technologies, Owen Mumford, PreciHealth, Recipharm, Sanofi, SHL Medical, Teva Pharmaceuticals, Union Medico and Ypsomed.

Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
+44 (122) 391 1091
Email: Gaurav.chaudhary@rootsanalysis.com or sales@rootsanalysis.com
Website: https://www.rootsanalysis.com

Roots Analysis is a global leader in the market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. All reports provided by us are structured in a way that enables the reader to develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we provide bespoke research / consulting services dedicated to serve our clients in the best possible way.

This release was published on openPR.